Mizuho Desk Comments on Replimune (REPL)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Barclays Downgrades Replimune Group (REPL) to Equalweight
July 22, 2025 4:31 PM EDTBarclays analyst Peter Lawson downgraded Replimune Group (NASDAQ: REPL) from Overweight to Equalweight with a price target of $3.00 (from $17.00).
The analyst comments "Downgrade to Equal Weight and lower PT to $3 following the surprising CRL issued by FDA for RP1+PD1 combo, which places... More
Leerink Partners Reiterates Outperform Rating on Replimune Group (REPL), PT $21, 'Estimates Under Review'
July 22, 2025 10:20 AM EDTLeerink Partners analyst Jonathan Chang reiterated an Outperform rating and $21.00 price target on Replimune Group (NASDAQ: REPL)
The analyst comments "Bottom Line: The FDA has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec; GALV, GM-CSF oncolytic virus) + nivolumab in anti-PD-1-failed melanoma. This update will likely come as a... More
Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'
July 22, 2025 8:50 AM EDTBarclays analyst Peter Lawson reiterated an Overweight rating and $17.00 price target on Replimune Group (NASDAQ: REPL).
The analyst comments "FDA issued a CRL for Replimune's BLA for RP1 in combo with nivo for PD1-refractory melanoma patients. While no safety concerns were raised, FDA cited issues around trial design and evidence of efficacy. This represents a positive read through to Iovance (IOVA, OW) with reduced competitive threat. Our key takeaways from Replimune's... More
Replimune receives FDA rejection letter for melanoma treatment
July 22, 2025 7:03 AM EDTReplimune Group, Inc. (NASDAQ: REPL) received a Complete Response Letter from the U.S. Food and Drug Administration rejecting its application for RP1 in combination with nivolumab for treating advanced melanoma.
The FDA stated the IGNYTE trial does not constitute an adequate and well-controlled clinical investigation providing substantial evidence of effectiveness. The agency cited... More
